FDA Approves METHYLPHENIDATE HYDROCHLORIDE — Granules Pharmaceuticals Inc.
Granules Pharmaceuticals Inc. secured FDA approval for its Abbreviated New Drug Application of methylphenidate hydrochloride tablets, unlocking a significant revenue opportunity in the ADHD therapeutics market. This launch is poised to increase competitive pressure against branded products and drive price competition within the generic segment.
AI-generated summary for informational purposes only. Always verify against the original filing. Not investment advice. BriefTape is not a registered investment adviser.
Get real-time financial news in your trading bot or app
GET FREE KEY — 10,000 calls/day